A Western blot assay demonstrated that there is no significant difference for the expression levels of RAF and VEGFR between the tumour cells derived from sorafenib sensitive patients and tumour cells derived from sorafenib resistant patients (Figure 1A). This evidence concerns the gene KDR and neoplasm.